Literature DB >> 12167769

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.

Kevin St P McNaught1, Lars M Björklund, Roger Belizaire, Ole Isacson, Peter Jenner, C Warren Olanow.   

Abstract

Structural and functional defects in 26/20S proteasomes occur in the substantia nigra pars compacta and may underlie protein accumulation, Lewy body formation and dopaminergic neuronal death in Parkinson's disease. We therefore determined the pathogenicity of proteasomal impairment following stereotaxic unilateral infusion of lactacystin, a selective proteasome inhibitor, into the substantia nigra pars compacta of rats. These animals became progressively bradykinetic, adopted a stooped posture and displayed contralateral head tilting. Administration of apomorphine to lactacystin-treated rats reversed behavioral abnormalities and induced contralateral rotations. Lactacystin caused dose-dependent degeneration of dopaminergic cell bodies and processes with the cytoplasmic accumulation and aggregation of alpha-synuclein to form inclusion bodies. These findings support the notion that failure of the ubiquitin-proteasome system to degrade and clear unwanted proteins is an important etiopathogenic factor in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167769     DOI: 10.1097/00001756-200208070-00018

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  61 in total

1.  Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.

Authors:  Catherine Meyer-Schwesinger; Tobias N Meyer; Henning Sievert; Elion Hoxha; Marlies Sachs; Eva-Maria Klupp; Silvia Münster; Stefan Balabanov; Lucie Carrier; Udo Helmchen; Friedrich Thaiss; Rolf A K Stahl
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

4.  Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Authors:  Chaoshi Niu; Jiaming Mei; Qi Pan; Xianming Fu
Journal:  Stereotact Funct Neurosurg       Date:  2009-02-18       Impact factor: 1.875

5.  Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.

Authors:  Joanna L Elson; Rafael Kochaj; Richard Reynolds; Ilse S Pienaar
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

6.  Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.

Authors:  Cheryl Dixon; Neal Mathias; Richard M Zweig; Donnie A Davis; David S Gross
Journal:  Genetics       Date:  2005-03-02       Impact factor: 4.562

7.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

Review 8.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

Review 9.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.